TrialDiabetologia2009

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

V Charlton-Menys et al.PubMed ↗Publisher ↗

It states no comparison between the randomised groups of NCT00327418. The report of the trial’s main result is not on the map, and the numbers here are shown and do not vote.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower lipids

−32.0percentage points−51.2 to −5.40

As reported

difference −32.0 %, 95% CI −51.2 to −5.40

One number in the abstract

the abstract, start to end

… ratio on atorvastatin predicted a 32% (95% CI 5.4-51.2%) risk …

← favours treatmentfavours comparator →

could be chance

Lipids

−32.0−51.2 to −5.40

StatinsLipids

1 / 3

16 papers cite it

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

The trial

NCT00327418phase 42,800 enrolled1997a later paper about it